Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06267846 | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder | PHASE2 | COMPLETED | 73 | — | — | Mar 20, 2024 | Sep 11, 2025 | Oct 29, 2025 | 13 | United States |
| Arm | Type | Description |
|---|---|---|
| NBI-1070770: Low Dose | EXPERIMENTAL | Participants will receive low-dose NBI-1070770. |
| NBI-1070770: Medium Dose | EXPERIMENTAL | Participants will receive medium-dose NBI-1070770. |
| NBI-1070770: High Dose | EXPERIMENTAL | Participants will receive high-dose NBI-1070770. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive matching placebo. |
| Name | Type | Description |
|---|---|---|
| NBI-1070770 | DRUG | Suspension for oral administration |
| Placebo | DRUG | Suspension for oral administration |
Key Inclusion Criteria: Participants must meet all of the following inclusion criteria: * Primary diagnosis of recurrent MDD or persistent MDD. * Participants currently receiving pharmacological treatment for depression must have been taking current antidepressant medication(s) for ≥8 weeks prior ...